Clients routinely have expressed the overwhelming need to get to the First-in-Human (Phase I) clinical trials as quickly as possible to generate safety for the IND submission. Several factors are behind this need, including discovery of much-needed innovative therapies, intense completion among developers in areas such as oncology, the need for small startups to reach the next milestone quickly in order to secure additional funding and more.
Recognizing this need, Pharma Services has recently introduced its Quick to Clinic™ program for biologics drug development. This program is Fast, Flexible and Full.
How it works:
More information on Quick to Clinic™ can be found here.
SOURCE: Patheon, part of Thermo Fisher Scientific